Human Tumor Antigens and Cancer Immunotherapy

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Jul 11

PMID 26161423

Citations 92

Authors

Nathalie Vigneron

Affiliations

Soon will be listed here.

Abstract

With the recent developments of adoptive T cell therapies and the use of new monoclonal antibodies against the immune checkpoints, immunotherapy is at a turning point. Key players for the success of these therapies are the cytolytic T lymphocytes, which are a subset of T cells able to recognize and kill tumor cells. Here, I review the nature of the antigenic peptides recognized by these T cells and the processes involved in their presentation. I discuss the importance of understanding how each antigenic peptide is processed in the context of immunotherapy and vaccine delivery.

Citing Articles

Alternative Splicing as a Modulator of the Interferon-Gamma Pathway.

Suri P, Badalov A, Ruggiu M Cancers (Basel). 2025; 17(4).

PMID: 40002189 PMC: 11853465. DOI: 10.3390/cancers17040594.

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against -mutant melanoma.

Poudel K, Ji Z, Njauw C, Rajadurai A, Bhayana B, Sullivan R Bioact Mater. 2025; 46():347-364.

PMID: 39834347 PMC: 11742834. DOI: 10.1016/j.bioactmat.2024.12.023.

mRNA vaccines: a new era in vaccine development.

Chandra S, Wilson J, Good D, Wei M Oncol Res. 2024; 32(10):1543-1564.

PMID: 39308511 PMC: 11413818. DOI: 10.32604/or.2024.043987.

Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.

Aparicio B, Theunissen P, Hervas-Stubbs S, Fortes P, Sarobe P Hum Vaccin Immunother. 2024; 20(1):2303799.

PMID: 38346926 PMC: 10863374. DOI: 10.1080/21645515.2024.2303799.

References

Shen X, Billet S, Lin C, Okwan-Duodu D, Chen X, Lukacher A . The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol. 2011; 12(11):1078-85. PMC: 3197883. DOI: 10.1038/ni.2107. View

Lebbe C, Weber J, Maio M, Neyns B, Harmankaya K, Hamid O . Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014; 25(11):2277-2284. PMC: 4990834. DOI: 10.1093/annonc/mdu441. View

Coulie P, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C . A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994; 180(1):35-42. PMC: 2191574. DOI: 10.1084/jem.180.1.35. View

Gueckel R, Enenkel C, Wolf D, Hilt W . Mutations in the yeast proteasome beta-type subunit Pre3 uncover position-dependent effects on proteasomal peptidase activity and in vivo function. J Biol Chem. 1998; 273(31):19443-52. DOI: 10.1074/jbc.273.31.19443. View

Griffith T, Brunner T, Fletcher S, Green D, Ferguson T . Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995; 270(5239):1189-92. DOI: 10.1126/science.270.5239.1189. View

Kessler J, Khan S, Seifert U, Le Gall S, Chow K, Paschen A . Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol. 2010; 12(1):45-53. DOI: 10.1038/ni.1974. View

Dunachie S, Hill A . Prime-boost strategies for malaria vaccine development. J Exp Biol. 2003; 206(Pt 21):3771-9. DOI: 10.1242/jeb.00642. View

Wolchok J, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L . Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2009; 11(2):155-64. DOI: 10.1016/S1470-2045(09)70334-1. View

Morgan R, Chinnasamy N, Abate-Daga D, Gros A, Robbins P, Zheng Z . Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36(2):133-51. PMC: 3581823. DOI: 10.1097/CJI.0b013e3182829903. View

10.

de Verteuil D, Muratore-Schroeder T, Granados D, Fortier M, Hardy M, Bramoulle A . Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics. 2010; 9(9):2034-47. PMC: 2938112. DOI: 10.1074/mcp.M900566-MCP200. View

11.

Asemissen A, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S . Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res. 2006; 12(24):7476-82. DOI: 10.1158/1078-0432.CCR-06-1337. View

12.

Driscoll J, Brown M, Finley D, Monaco J . MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature. 1993; 365(6443):262-4. DOI: 10.1038/365262a0. View

13.

Hammarstrom S . The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999; 9(2):67-81. DOI: 10.1006/scbi.1998.0119. View

14.

McMichael A . HIV vaccines. Annu Rev Immunol. 2006; 24:227-55. DOI: 10.1146/annurev.immunol.24.021605.090605. View

15.

Nussbaum A, Dick T, Keilholz W, Schirle M, Stevanovic S, Dietz K . Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A. 1998; 95(21):12504-9. PMC: 22860. DOI: 10.1073/pnas.95.21.12504. View

16.

Zarling A, Polefrone J, Evans A, Mikesh L, Shabanowitz J, Lewis S . Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci U S A. 2006; 103(40):14889-94. PMC: 1595446. DOI: 10.1073/pnas.0604045103. View

17.

Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, De Plaen E . A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995; 269(5228):1281-4. DOI: 10.1126/science.7652577. View

18.

Dahlmann B, Ruppert T, Kuehn L, Merforth S, Kloetzel P . Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol. 2000; 303(5):643-53. DOI: 10.1006/jmbi.2000.4185. View

19.

Coulie P, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M . A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995; 92(17):7976-80. PMC: 41269. DOI: 10.1073/pnas.92.17.7976. View

20.

Kruit W, van Ojik H, Brichard V, Escudier B, Dorval T, Dreno B . Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer. 2005; 117(4):596-604. DOI: 10.1002/ijc.21264. View